scispace - formally typeset
Open AccessJournal ArticleDOI

Myeloma: A malignant disorder of bone and soft tissue

Reads0
Chats0
TLDR
Despite many efforts over the years and the large number of treatment agents introduced, it is apparent that the authors do not have sufficient ability or knowledge to control this very troublesome disorder.
Abstract
The purpose of this brief report is to review a large series of cases of myeloma, a highly malignant tumor.  The disease was first described over 150 years ago, but not named myeloma until 1873. The lesion appears to be caused by the production of plasma cells in the bone marrow occasionally associated with amyloid. Patients present with pain in bones, principally spine, pelvis, ribs, calvarium and long bones. The sedimentation rate is elevated and marrow shows 10% plasma cells and the sedimentation rate is always elevated.  There is no identified genetic cause and the disease is not familial. The disease has a highly malignant potential. We treated 181 mature adult patients with tumor in multiple sites. 63% were dead of disease at an average of  4.5 years after diagnosis. The use of some new drugs have been helpful, chiefly lalanlidomide or bortezomib. Radiation appears to be useful for some lesions and bisphosphonates sometimes help support the bone structure. Despite many efforts over the years and the large number of treatment agents introduced, it is apparent that we do not have sufficient ability or knowledge to control this very troublesome disorder.

read more

Content maybe subject to copyright    Report

References
More filters
Journal ArticleDOI

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

TL;DR: Initial staging can be quantitatively related to followup using tumor cell mass changes calculated from changes in M‐component production, and should lead to improved study design and analysis in large clinical trials of therapy for multiple myeloma.
Journal ArticleDOI

Chromosome translocations in multiple myeloma.

TL;DR: Oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation.